We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for tocilizumab (Roche Products Pty Limited)
Active ingredients
tocilizumab
Sponsor
Date of review outcome
Lapse date
Type
Provisional approval
Indication
Coronavirus disease 2019 (COVID-19) (IV formulation only) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation
Therapeutic area
Infectious diseases